We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+26.26%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$858M
AUM Growth
-$99.6M
Cap. Flow
-$206M
Cap. Flow %
-24.01%
Top 10 Hldgs %
70.19%
Holding
45
New
7
Increased
7
Reduced
8
Closed
14

Top Buys

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$47.5M
2
TSRO
TESARO, Inc.
TSRO
+$26M
3
ACHN
Achillion Pharmaceuticals
ACHN
+$25.9M
4
XNCR icon
Xencor
XNCR
+$23.4M
5
DVAX
Dynavax Technologies
DVAX
+$17.4M

Top Sells

Rank Stock Value
1
DYAX
DYAX CORPORATION
DYAX
+$66.8M
2
INSM icon
Insmed
INSM
+$46.6M
3
LUMO
Lumos Pharma, Inc. Common Stock
LUMO
+$36.4M
4
NVAX icon
Novavax
NVAX
+$35.3M
5
XOMA
Xoma
XOMA
+$31.1M

Sector Composition

Rank Sector Weight
1 Healthcare 72.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACAD icon
1
CALL
Acadia Pharmaceuticals
ACAD
$4.52B
$131M 15.28%
5,250,000
– –
ACHN
2
DELISTED
Achillion Pharmaceuticals
ACHN
$77.6M 9.03%
23,366,007
+8,908,946
+62% +$25.9M
SGMO
3
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$72.6M 8.46%
5,227,272
+969,028
+23% +$11.2M
TXMD icon
4
TherapeuticsMD
TXMD
$24M
$60.7M 7.08%
233,202
-97,371
-29% -$21.3M
NVAX icon
5
Novavax
NVAX
$1.22B
$55.4M 6.45%
540,594
-499,406
-48% -$35.3M
ISEE
6
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$51.8M 6.03%
+1,600,455
New +$47.5M
PRTA icon
7
Prothena Corp
PRTA
$450M
$43.5M 5.07%
1,641,167
-5,232
-0.3% -$131K
SGMO
8
CALL
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$41.7M 4.85%
3,000,000
– –
DVAX
9
DELISTED
Dynavax Technologies
DVAX
$35.1M 4.08%
1,788,395
+1,188,395
+198% +$17.4M
BCRX icon
10
BioCryst Pharmaceuticals
BCRX
$2.46B
$33M 3.85%
4,347,456
-1,497,244
-26% -$9.48M
ACAD icon
11
Acadia Pharmaceuticals
ACAD
$4.52B
$29.2M 3.41%
1,169,898
-865,612
-43% -$20.4M
XNCR icon
12
Xencor
XNCR
$1.47B
$24.9M 2.9%
+2,725,000
New +$23.4M
VIRX
13
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$23.1M 2.69%
23,187
– –
ARWR icon
14
Arrowhead Research
ARWR
$12.1B
$22.2M 2.59%
2,049,220
+1,169,659
+133% +$9.35M
DSCI
15
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$21.6M 2.51%
1,994,876
– –
TSRO
16
DELISTED
TESARO, Inc.
TSRO
$19.8M 2.3%
+700,000
New +$26M
PTCT icon
17
PTC Therapeutics
PTCT
$6.21B
$12.8M 1.49%
752,438
+452,438
+151% +$7.95M
DYAX
18
DELISTED
DYAX CORPORATION
DYAX
$12.2M 1.42%
1,619,697
-8,798,682
-84% -$66.8M
LUMO
19
CALL
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$11M 1.28%
55,556
– –
MRTX
20
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$10.9M 1.27%
656,767
+105,044
+19% +$1.8M
RMTI icon
21
PUT
Rockwell Medical
RMTI
$27.5M
$10.4M 1.22%
9,091
– –
ACHN
22
CALL
DELISTED
Achillion Pharmaceuticals
ACHN
$9.96M 1.16%
3,000,000
-2,500,000
-45% -$7.25M
BLUE
23
DELISTED
bluebird bio
BLUE
$9.81M 1.14%
36,085
– –
OCRX
24
DELISTED
Ocera Therapeutics, Inc.
OCRX
$8.6M 1%
661,696
+445,697
+206% +$4.16M
ENZ
25
DELISTED
Enzo Biochem, Inc.
ENZ
$6.62M 0.77%
2,268,653
-1,079,376
-32% -$2.68M
1
2

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q4 2013 Portfolio in Review

As of Q4 2013, RA Capital Management held 45 positions worth $858M, down 10% from $958M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

RA Capital Management withdrew a net $206M in Q4 2013, closing 14 positions and reducing 8 holdings. Its most notable exit was Insmed, an estimated $46.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, up from 64% a quarter earlier.

Against the trend, RA Capital Management opened a new position in IVERIC bio, Inc. Common Stock worth $51.8M.

  • RA Capital Management's largest Q4 2013 buy was IVERIC bio, Inc. Common Stock: 1,600,455 shares worth $51.8M.
  • RA Capital Management added most to Achillion Pharmaceuticals in Q4 2013, an estimated $25.9M increase.
  • RA Capital Management's biggest Q4 2013 reduction was DYAX CORPORATION, cutting an estimated $66.8M.
  • RA Capital Management fully exited Insmed in Q4 2013, selling an estimated $46.6M.
  • RA Capital Management's ten largest holdings make up 70% of its $858M portfolio in Q4 2013.
  • RA Capital Management opened 7 new positions and closed 14 in Q4 2013.
  • RA Capital Management's portfolio value fell 10% quarter-over-quarter to $858M.

Based on RA Capital Management's 13F filing for Q4 2013, filed 14 Feb 2014.